Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia

Area of Science:

• Microbiology
• Infectious Diseases
• Bacteriophage Therapy

Background:

• The rise of antibiotic-resistant bacteria necessitates novel therapeutic strategies.
• Acinetobacter baumannii is a significant cause of hospital-acquired infections, including pneumonia.
• Bacteriophages (phages) are viruses that infect bacteria and are being explored as alternatives to antibiotics.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a lytic bacteriophage against Acinetobacter baumannii pneumonia in a mouse model.
• To assess the impact of phage treatment on survival rates, bacterial load, and lung pathology.

Main Methods:

• A mouse pneumonia model was established using cyclophosphamide and Acinetobacter baumannii.
• Therapeutic efficacy was assessed via intranasal bacteriophage administration.
• Outcomes measured included survival rate, lung bacterial load, and lung inflammation via microcomputed tomography.

Main Results:

• Intranasal bacteriophage treatment resulted in 100% survival in mice challenged with a lethal dose of A. baumannii.
• Phage therapy significantly reduced bacterial load in the lungs.
• Microcomputed tomography revealed a reduction in lung inflammation.

Conclusions:

• Intranasal bacteriophage application is a viable and effective treatment for Acinetobacter baumannii pneumonia.
• Bacteriophage therapy offers complete protection and reduces inflammation, presenting a promising alternative to antibiotics.